BridgeBio Pharma, Inc.
BBIODrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
27dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How BBIO's past catalysts played out
Acoramidis
Amyloidosis
Encaleret
Autosomal Dominant Hypocalcemia (ADH)
AG10
Familial ATTR-CM (ATTRm-CM, or FAC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Acoramidis | Phase 3 | Amyloidosis | - | - |
Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) | - | - |
AG10 | Phase 2 | Familial ATTR-CM (ATTRm-CM, or FAC) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BridgeBio Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in BridgeBio Pharma, Inc.'s (BBIO) pipeline across Phase 3, Phase 2. Its lead program is Acoramidis (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BridgeBio Pharma, Inc.'s next FDA catalyst?→
BridgeBio Pharma, Inc.'s (BBIO) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BBIO biotech catalysts?→
Add BBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BridgeBio Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.